D. Veach

发表

Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).

John Kuriyan, J. Kuriyan, W. Bornmann, 2001, Cancer research.

Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase

G. Superti-Furga, O. Hantschel, J. Kuriyan, 2003, Cell.

Evaluation of Castration-Resistant Prostate Cancer with Androgen Receptor–Axis Imaging

S. Larson, M. Morris, H. Scher, 2016, The Journal of Nuclear Medicine.

Cell Treatment and Lysis in 96-Well Filter-Bottom Plates for Screening Bcr-Abl Activity and Inhibition in Whole-Cell Extracts

D. Veach, S. Kron, M. Mand, 2010, Journal of biomolecular screening.

Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib.

S. Larson, M. Namavari, D. Veach, 2007, Journal of medicinal chemistry.

124I-Iodopyridopyrimidinone for PET of Abl Kinase–Expressing Tumors In Vivo

S. Larson, W. Bornmann, D. Veach, 2010, Journal of Nuclear Medicine.

Two Distinct Phosphorylation Pathways Have Additive Effects on Abl Family Kinase Activation

H. Duewel, W. Bornmann, D. Veach, 2003, Molecular and Cellular Biology.

A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor.

W. Bornmann, D. Veach, B. Clarkson, 2005, Blood.

PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates

S. Larson, H. Scher, R. Damoiseaux, 2020, Clinical Cancer Research.

Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling

S. Larson, N. Bander, D. Spratt, 2016, EJNMMI Research.

Intraperitoneal Pretargeted Radioimmunotherapy for Colorectal Peritoneal Carcinomatosis

S. Larson, G. Nash, A. Cercek, 2021, Molecular Cancer Therapeutics.

Internalization of secreted antigen–targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis

S. Larson, P. Scardino, H. Scher, 2016, Science Translational Medicine.

Assessing Functional Androgen Receptor Pathway Activity in Response to Radiotherapy Using hK2-targeted PET Imaging

S. Larson, R. Klein, R. Damoiseaux, 2022, bioRxiv.

Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas.

W. Gerald, W. Travis, W. Pao, 2007, The Journal of clinical investigation.

the mutation pattern for PD166326, an alternative Abl kinase inhibitor A cell-based screen for resistance of Bcr-Abl positive leukemia identifies

W. Bornmann, D. Veach, B. Clarkson, 2012 .

Direct engagement of the PI3K pathway by mutant KIT dominates oncogenic signaling in gastrointestinal stromal tumor

C. Antonescu, K. Manova, R. DeMatteo, 2017, Proceedings of the National Academy of Sciences.

In vivo immuno-targeting of an extracellular epitope of membrane bound preferentially expressed antigen in melanoma (PRAME)

S. Larson, M. McDevitt, D. Veach, 2017, Oncotarget.

ImmunoPET Imaging of Endogenous and Transfected Prolactin Receptor Tumor Xenografts.

Valerie A Longo, Jason T Giurleo, S. Larson, 2018, Molecular pharmaceutics.

Positron Emission Tomography/Computed Tomography–Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer

S. Nehmeh, J. Humm, S. Larson, 2017, JAMA oncology.

A N-acetylgalactosamino Dendron-Clearing Agent for High-Therapeutic Index DOTA-Hapten Pretargeted Radioimmunotherapy.

S. Larson, N. Cheung, D. Veach, 2019, Bioconjugate chemistry.

Engineered Cells as a Test Platform for Radiohaptens in Pretargeted Imaging and Radioimmunotherapy Applications.

S. Larson, D. Scheinberg, M. McDevitt, 2021, Bioconjugate chemistry.

Harnessing Androgen Receptor Pathway Activation for Targeted Alpha Particle Radioimmunotherapy of Breast Cancer

S. Larson, Jason S. Lewis, H. Lilja, 2018, Clinical Cancer Research.

Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted α-particle therapy

S. Larson, R. Klein, M. Phelps, 2020, Proceedings of the National Academy of Sciences.

Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer

S. Larson, P. Scardino, H. Scher, 2018, Nature Communications.

Remodelling the vascular microenvironment of glioblastoma with alpha-particles

P. Gutin, D. Scheinberg, M. McDevitt, 2016 .

A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted Radioimmunotherapy

S. Larson, C. Rudin, M. McDevitt, 2020, Clinical Cancer Research.

Dosimetry of 18F-Labeled Tyrosine Kinase Inhibitor SKI-249380, a Dasatinib-Tracer for PET Imaging

S. Larson, Jason S. Lewis, R. Somwar, 2012, Molecular Imaging and Biology.

A fluorine-labeled methotrexate as a probe for monitoring tumor antifolate pharmacokinetics: synthesis, in vitro cytotoxicity, and pilot in vivo 19F magnetic resonance spectra.

J. Koutcher, W. Bornmann, D. Veach, 2003, Molecular cancer therapeutics.

Structure-activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: toward selective Abl inhibitors.

D. Veach, B. Clarkson, C. Antczak, 2009, Bioorganic & medicinal chemistry letters.

Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases.

J. Kuriyan, J. Bertino, W. Bornmann, 2002, Cancer research.

Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate

J. Melo, W. Bornmann, D. Veach, 2003, Leukemia.

DNA photocleavage and biological activity of a pyrene dihydrodioxin.

D. Veach, E. T. Mack, R. Wilson, 2005, Bioorganic & Medicinal Chemistry Letters.

L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition

Narasimhan P. Agaram, C. Antonescu, M. Weiser, 2007, International journal of cancer.

Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases

M. Feinberg, D. Kalman, W. Bornmann, 2005, Nature Medicine.

Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors.

W. Bornmann, D. Veach, W. Miller, 2003, Cancer Research.

Genetic signature of prostate cancer resistant to optimized hK2 targeted alpha-particle therapy

S. Larson, R. Klein, M. Morris, 2019, bioRxiv.

Fluorine-labeled dasatinib nanoformulations as targeted molecular imaging probes in a PDGFB-driven murine glioblastoma model.

Valerie A Longo, Evan Phillips, Tatsuya Ozawa, 2012, Neoplasia.

Increased KIT Inhibition Enhances Therapeutic Efficacy in Gastrointestinal Stromal Tumor

Eric C. Sorenson, C. Antonescu, R. DeMatteo, 2014, Clinical Cancer Research.

Cancer Therapy : Preclinical Increased KIT Inhibition Enhances Therapeutic Ef fi cacy in Gastrointestinal Stromal Tumor

Eric C. Sorenson, C. Antonescu, R. DeMatteo, 2014 .

Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance.

Piotr Sliz, Mohammad Azam, Tomi K Sawyer, 2006, Proceedings of the National Academy of Sciences of the United States of America.

Synthesis and in vitro examination of [124I]-, [125I]- and [131I]-2-(4-iodophenylamino) pyrido[2,3-d]pyrimidin-7-one radiolabeled Abl kinase inhibitors.

S. Larson, M. Namavari, W. Bornmann, 2005, Nuclear medicine and biology.

Loss of p53 impedes the antileukemic response to BCR-ABL inhibition.

S. Lowe, W. McCombie, J. Fridman, 2006, Proceedings of the National Academy of Sciences of the United States of America.

Sorafenib Inhibits the Imatinib-Resistant KITT670I Gatekeeper Mutation in Gastrointestinal Stromal Tumor

Narasimhan P. Agaram, C. Antonescu, S. Singer, 2007, Clinical Cancer Research.

Remodeling the Vascular Microenvironment of Glioblastoma with α-Particles

P. Gutin, D. Scheinberg, M. McDevitt, 2016, The Journal of Nuclear Medicine.

Caenorhabditis elegans ABL-1 antagonizes p53-mediated germline apoptosis after ionizing irradiation

O. Hobert, C. Cordon-Cardo, M. Hengartner, 2004, Nature Genetics.

A magnetic bead-based protein kinase assay with dual detection techniques.

D. Veach, S. Kron, Ding Wu, 2011, Analytical biochemistry.

Quantification of change in phosphorylation of BCR‐ABL kinase and its substrates in response to Imatinib treatment in human chronic myelogenous leukemia cells

M. Resh, D. Veach, B. Clarkson, 2006, Proteomics.

Enteropathogenic Escherichia coli use redundant tyrosine kinases to form actin pedestals.

D. Kalman, W. Bornmann, D. Veach, 2004, Molecular biology of the cell.

tumors harboring KIT AY502-3ins mutation: an in vitro mutagenesis screen for drug-resistance

Narasimhan P. Agaram, C. Antonescu, S. Singer, 2010 .

Mechanisms of Sunitinib Resistance in Gastrointestinal Stromal Tumors Harboring KITAY502-3ins Mutation: An In vitro Mutagenesis Screen for Drug Resistance

Narasimhan P. Agaram, C. Antonescu, S. Singer, 2009, Clinical Cancer Research.

Imatinib resistance and microcytic erythrocytosis in a KitV558Δ;T669I/+ gatekeeper-mutant mouse model of gastrointestinal stromal tumor

C. Antonescu, K. Manova-Todorova, E. de Stanchina, 2012, Proceedings of the National Academy of Sciences.

of gastrointestinal stromal tumor

C. Antonescu, E. Stanchina, K. Manova-Todorova, 2012 .

PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.

W. Bornmann, D. Veach, R. Ilaria, 2005, Blood.

Imatinib Upregulates Compensatory Integrin Signaling in a Mouse Model of Gastrointestinal Stromal Tumor and Is More Effective When Combined with Dasatinib

C. Antonescu, K. Manova, F. Giancotti, 2010, Molecular Cancer Research.

Gleevec inhibits β-amyloid production but not Notch cleavage

Paul Greengard, Darren R. Veach, William G. Bornmann, 2003, Proceedings of the National Academy of Sciences of the United States of America.

c-Kit Receptor Tyrosine Kinases Characterization of Potent Inhibitors of the Bcr-Abl and the Updated

J. Kuriyan, J. Bertino, W. Bornmann, 2002 .

Gleevec inhibits beta-amyloid production but not Notch cleavage.

P. Greengard, Yueming Li, W. Netzer, 2003, Proceedings of the National Academy of Sciences of the United States of America.

A solid-phase Bcr-Abl kinase assay in 96-well hydrogel plates.

D. Veach, B. Clarkson, S. Kron, 2008, Analytical biochemistry.

Alpha radioimmunotherapy using 225Ac-proteus-DOTA for solid tumors - safety at curative doses

S. Larson, D. Scheinberg, M. McDevitt, 2020, Theranostics.

Molecular Cancer esearch aling and Regulation tinib Upregulates Compensatory Integrin Signaling in a se Model of Gastrointestinal Stromal Tumor and Is More R ctive When Combined with Dasatinib

C. Antonescu, K. Manova, E. Stanchina, 2010 .

First-in-Humans Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted PET

S. Larson, M. Voss, Jason S. Lewis, 2020, The Journal of Nuclear Medicine.

Efficacy of HER2-Targeted Intraperitoneal 225Ac α-Pretargeted Radioimmunotherapy for Small-Volume Ovarian Peritoneal Carcinomatosis

S. Larson, M. McDevitt, G. Nash, 2023, The Journal of Nuclear Medicine.

Fluorescent monitoring of kinase activity in real time: development of a robust fluorescence-based assay for Abl tyrosine kinase activity.

T. Muir, W. Bornmann, D. Veach, 2001, Bioorganic & medicinal chemistry letters.

Quantitative In Vivo Imaging of the Androgen Receptor Axis Reveals Degree of Prostate Cancer Radiotherapy Response.

S. Larson, R. Klein, R. Damoiseaux, 2023, Molecular cancer research : MCR.

Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer

S. Larson, P. Scardino, H. Scher, 2018, Nature Communications.

Engineering CAR-T cells for radiohapten capture in imaging and radioimmunotherapy applications

D. Scheinberg, D. Veach, H. Schöder, 2023, Theranostics.

BCR-ABL Kinase Dynamics and Drug Resistance.

G. Daley, D. Veach, R. Latek, 2005 .